Fortrea (NASDAQ:FTRE) Misses Q4 Revenue Estimates, Stock Drops
Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...
Fortrea: A Growing CRO With Strong Backlog, Margin Expansion, And Industry Tailwinds
Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...
William Blair Has Pessimistic Outlook of Fortrea Q4 Earnings
Research analysts at William Blair cut their Q4 2025 earnings estimates for Fortrea in a research report issued to clients ...
Fortrea (NASDAQ:FTRE) Price Target Cut to $12.00 by Analysts at Barclays
Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...
Fortrea Faces Spin-Related Challenges in the Near Term; Positive Long-Term Outlook
We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...
Q4 2024 Fortrea Holdings Inc Earnings Call
Ladies and gentlemen, thank you for standing by, and welcome to Fortrea fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being ...
Fortrea price target lowered to $10 from $17 at BofA
BofA lowered the firm’s price target on Fortrea (FTRE) to $10 from $17 and keeps an Underperform rating on the shares after a Q4 miss and FY25 ...
Fortrea price target lowered to $12 from $25 at Barclays
Barclays lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps an Equal Weight rating on the shares.Discover the Best ...
Fortrea Expects Revenue Decline in 2025
The contract-research organization expects $2.45 billion to $2.55 billion in revenue for 2025, down from $2.7 billion last year. Analysts polled by FactSet had been forecasting a small gain to $2.73 ...